Inner-City Asthma Consortium
14
0
0
13
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
7.1%
1 terminated/withdrawn out of 14 trials
92.9%
+6.4% vs industry average
14%
2 trials in Phase 3/4
69%
9 of 13 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
Urban Environmental Factors and Childhood Asthma
Role: collaborator
Cockroach Immunotherapy in Children and Adolescents
Role: collaborator
A Trial of Mepolizumab Adjunctive Therapy for the Prevention of Asthma Exacerbations in Urban Children
Role: collaborator
Registry for Asthma Characterization and Recruitment 2
Role: collaborator
Cockroach Nasal Allergen Challenge Pilot
Role: collaborator
Subcutaneous Immunotherapy for Mouse in Adults
Role: collaborator
Mechanisms Underlying Asthma Exacerbations Prevented and Persistent With Immune-Based Therapy
Role: collaborator
Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations
Role: collaborator
Inner-City Anti-IgE Therapy for Asthma
Role: collaborator
Biomarker-based Cockroach Sublingual Immunotherapy Study (BioCSI)
Role: collaborator
Asthma Phenotypes in the Inner City
Role: collaborator
Sublingual Cockroach Safety in Adults With Cockroach Allergy & Perennial Allergic Rhinitis With or Without Asthma
Role: collaborator
Development of Cockroach Immunotherapy by the Inner-City Asthma Consortium
Role: collaborator
Comparing Allergenic Effects of 3 German Cockroach Extracts in Adults
Role: collaborator
All 14 trials loaded